Beam Therapeutics

Beam Therapeutics

Biotechnology Research

Cambridge, Massachusetts 62,515 followers

Our vision is to provide life-long cures for patients suffering from serious diseases.

About us

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other

Website
http://beamtx.com
Industry
Biotechnology Research
Company size
501-1,000 employees
Headquarters
Cambridge, Massachusetts
Type
Public Company
Founded
2017
Specialties
gene therapy, base editing, gene editing, precision medicines, CRISPR, CRISPR Cas9, genetic diseases, rare diseases, hematology, lipid nanoparticles, LNP, vector production, AAV, In vivo, ex vivo, Liver, mRNA Production, mRNA, DNA, RNA, Cas9, drug development, drug delivery, immunology, formulation development, virology, viral delivery, nanoparticles formulation, structural biology, cell biology, protein sciences, and cell therapy

Locations

Employees at Beam Therapeutics

Updates

Similar pages

Browse jobs

Funding

Beam Therapeutics 4 total rounds

Last Round

Post IPO equity

US$ 260.0M

See more info on crunchbase